HS-10353

HS-10353 is an investigational small molecule drug developed by Jiangsu Hansoh Pharmaceutical for the treatment of major depressive disorder and postpartum depression. It acts as a positive allosteric modulator of the Gamma-aminobutyric acid A receptor (GABAA receptor), aiming to correct dysfunction in GABAergic signaling and restore balance between GABA and NMDA receptor activity. As an oral preparation with allopregnanolone-like properties, it is designed for rapid onset, good bioavailability, and high safety. Clinical development is ongoing in China, with Phase II trials underway for both major depressive disorder and postpartum depression[1][2][3][5].